Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

NCT06670352 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy (IgAN)

Interventions

DRUG: Placebo
DRUG: HSK39297 50mgBID
DRUG: HSK39297 100mgBID
DRUG: HSK39297 200mgQD

Sponsor

Haisco Pharmaceutical Group Co., Ltd.